|
Evaluating ADGRB3 as a tumor suppressor epigenetically silenced in WNT medulloblastoma |
3R01CA235162-04S1 |
|
NCI |
2022 |
|
Investigating Microenvironmental Interactions in Leptomeningeal Metastasis |
5R01CA245499-03 |
|
NCI |
2022 |
|
Comparison of Symptom Burden/Toxicity, Neurocognitive Change, and Functional Outcomes in Pediatric Brain Tumor Patients Treated with Proton vs. Photon Radiotherapy. |
1 R01 CA249988-01A1 |
|
NCI |
2021 |
|
Endovascular ChemoFilter to Reduce Doxorubicin Toxicity during Intra-Arterial Chemotherapy |
1 R42 CA265316-01 |
|
NCI |
2021 |
|
Mechanisms of leukemogenesis in Down syndrome |
5 R01 CA101774-20 |
CRISPINO, JOHN D |
NCI |
2021 |
|
INTERFERON SIGNALING AND THE DIFFERENTIAL MALIGNANCY SPECTRUM OF DOWN SYNDROME |
3P30CA046934-31S6 |
SCHULICK, RICHARD D |
NCI |
2019 |
|
MECHANISMS OF LEUKEMOGENESIS IN DOWN SYNDROME |
5R01CA101774-17 |
CRISPINO, JOHN D |
NCI |
2019 |
|
MECHANISMS OF HUMAN IMMUNE MODULATION BY ORAL N-ACETYLGLUCOSAMINE |
5R01AT007452-05 |
DEMETRIOU, MICHAEL |
NCCIH |
2018 |
|
DEEP PHENOTYPING AND PAN-OMICS OF ACUTE LYMPHOBLASTIC LEUKEMIA IN DOWN SYNDROME |
3P30CA125123-12S4 |
OSBORNE, C KENT |
NCI |
2018 |
|
MECHANISMS OF LEUKEMOGENESIS IN DOWN SYNDROME |
3R01CA101774-16S1 |
CRISPINO, JOHN D |
NCI |
2018 |